Myeloma Trial, Recruiting (NCT06357754)

Myeloma Trial, Recruiting NCT06357754 Sponsor: Bristol-Myers Squibb Condition: Myeloma

Printed from Voxsanity (voxsanity.com.au) — NCT06357754 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Myeloma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have previously received a commercially available gene-modified cell therapy made by Bristol-Myers Squibb (BMS), and who have since been diagnosed with a specific type of new, separate cancer that BMS has identified as qualifying for this study.
People who received a BMS-made gene-modified cell therapy as part of a clinical trial or other research setting (including cases where the product did not meet standard specifications), where no separate testing program is already in place for that trial or research setting, and who have since been diagnosed with a specific type of new, separate cancer that BMS has identified as qualifying for this study.

Who may not be able to join:

People who are currently enrolled in another clinical trial that is already collecting information and samples related to this same issue.
People who have not received a BMS-made gene-modified cell therapy, or who have not been diagnosed with a qualifying new, separate cancer as defined by BMS.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb

Phone: 855-907-3286

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06357754

Sponsor: Bristol-Myers Squibb

Phase: Not Applicable

Status: Recruiting

Condition: Myeloma

Trial contact: 855-907-3286

More information: https://clinicaltrials.gov/study/NCT06357754

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have previously received a commercially available gene-modified cell therapy made by Bristol-Myers Squibb (BMS), and who have since been diagnosed with a specific type of new, separate cancer that BMS has identified as qualifying for this study.
People who received a BMS-made gene-modified cell therapy as part of a clinical trial or other research setting (including cases where the product did not meet standard specifications), where no separate testing program is already in place for that trial or research setting, and who have since been diagnosed with a specific type of new, separate cancer that BMS has identified as qualifying for this study.

Who may not be able to join:

People who are currently enrolled in another clinical trial that is already collecting information and samples related to this same issue.
People who have not received a BMS-made gene-modified cell therapy, or who have not been diagnosed with a qualifying new, separate cancer as defined by BMS.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Bristol-Myers Squibb

Registry

ClinicalTrials.gov

Start date

6 October 2023

Est. completion

6 October 2038

Where this trial is recruiting

🇩🇪 Germany 🇯🇵 Japan 🇨🇭 Switzerland 🇺🇸 United States

Primary endpoints

Participant in situ hybridization (ISH) or droplet-based digital Polymerase chain reaction (ddPCR) transgene testing results; Participant insertion site analysis (ISA) testing results

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov